{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T22:35:16Z","timestamp":1785191716372,"version":"3.55.0"},"reference-count":31,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T00:00:00Z","timestamp":1701043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI22\/00514"],"award-info":[{"award-number":["PI22\/00514"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["ED431B 2020\/37"],"award-info":[{"award-number":["ED431B 2020\/37"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010801","name":"European Union","doi-asserted-by":"publisher","award":["PI22\/00514"],"award-info":[{"award-number":["PI22\/00514"]}],"id":[{"id":"10.13039\/501100010801","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010801","name":"European Union","doi-asserted-by":"publisher","award":["ED431B 2020\/37"],"award-info":[{"award-number":["ED431B 2020\/37"]}],"id":[{"id":"10.13039\/501100010801","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fundaci\u00f3n Alfonso Mart\u00edn Escudero","award":["PI22\/00514"],"award-info":[{"award-number":["PI22\/00514"]}]},{"name":"Fundaci\u00f3n Alfonso Mart\u00edn Escudero","award":["ED431B 2020\/37"],"award-info":[{"award-number":["ED431B 2020\/37"]}]},{"name":"Asociaci\u00f3n Espa\u00f1ola de Familiares y Afectados de Lipodistrofias (AELIP)","award":["PI22\/00514"],"award-info":[{"award-number":["PI22\/00514"]}]},{"name":"Asociaci\u00f3n Espa\u00f1ola de Familiares y Afectados de Lipodistrofias (AELIP)","award":["ED431B 2020\/37"],"award-info":[{"award-number":["ED431B 2020\/37"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Acquired generalised lipodystrophy (AGL) is a rare disorder characterised by the gradual loss of fat that tends to generalise over time, the origin of which is still not fully clarified. The aim of this study was to offer a detailed description of seven patients with AGL (five women, 33.8 \u00b1 18.6 years of age), evaluated over the last 14 years, in order to augment the knowledge of this disorder. The onset of the phenotype occurred during childhood and adolescence in five cases, and in adulthood in two cases. Three patients reported infections or vaccine administration prior to the development of lipodystrophy, and two subjects reported nodular swelling. The most frequent physical features were phlebomegaly, umbilical protrusion\/hernia, and acanthosis nigricans. Skinfolds and body composition analysis showed the generalised absence of fat, with the exception of one patient in whom fat loss was spared in the trunk. The loss of fat in the palms\/soles was observed in five subjects. Regarding metabolic comorbidities, throughout follow-up, two patients developed type 1 diabetes and one type 2 diabetes; three also presented hypertriglyceridaemia, one of whom developed acute pancreatitis, and no macrovascular complications were observed. Only one patient showed decreased complement C4. Autoimmunity was present in all cases, and six patients manifested Hashimoto\u2019s thyroiditis, type 1 diabetes, autoimmune hepatitis, and\/or celiac disease. Thus, there are certain clinical characteristics of AGL that may be considered important diagnostic criteria to differentiate this disorder from other lipodystrophy subtypes.<\/jats:p>","DOI":"10.3390\/jcm12237344","type":"journal-article","created":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T07:56:10Z","timestamp":1701071770000},"page":"7344","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinical Characterisation and Comorbidities of Acquired Generalised Lipodystrophy: A 14-Year Follow-Up Study"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1268-7538","authenticated-orcid":false,"given":"Antia","family":"Fernandez-Pombo","sequence":"first","affiliation":[{"name":"UETeM-Molecular Pathology Group, Department of Psychiatry, Radiology, Public Health, Nursing and Medicine, IDIS-CIMUS, University of Santiago de Compostela, 15706 Santiago de Compostela, Spain"},{"name":"Division of Endocrinology and Nutrition, University Clinical Hospital of Santiago de Compostela, 15706 Santiago de Compostela, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Prado-Mora\u00f1a","sequence":"additional","affiliation":[{"name":"UETeM-Molecular Pathology Group, Department of Psychiatry, Radiology, Public Health, Nursing and Medicine, IDIS-CIMUS, University of Santiago de Compostela, 15706 Santiago de Compostela, Spain"},{"name":"Division of Endocrinology and Nutrition, University Clinical Hospital of Santiago de Compostela, 15706 Santiago de Compostela, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Everardo Josue","family":"Diaz-Lopez","sequence":"additional","affiliation":[{"name":"UETeM-Molecular Pathology Group, Department of Psychiatry, Radiology, Public Health, Nursing and Medicine, IDIS-CIMUS, University of Santiago de Compostela, 15706 Santiago de Compostela, Spain"},{"name":"Division of Endocrinology and Nutrition, University Clinical Hospital of Santiago de Compostela, 15706 Santiago de Compostela, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3887-0573","authenticated-orcid":false,"given":"Sofia","family":"Sanchez-Iglesias","sequence":"additional","affiliation":[{"name":"UETeM-Molecular Pathology Group, Department of Psychiatry, Radiology, Public Health, Nursing and Medicine, IDIS-CIMUS, University of Santiago de Compostela, 15706 Santiago de Compostela, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana I.","family":"Castro","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Nutrition, University Clinical Hospital of Santiago de Compostela, 15706 Santiago de Compostela, Spain"},{"name":"CIBER Fisiopatologia de la Obesidad y la Nutricion (CIBERobn), 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0941-626X","authenticated-orcid":false,"given":"Silvia","family":"Cobelo-Gomez","sequence":"additional","affiliation":[{"name":"UETeM-Molecular Pathology Group, Department of Psychiatry, Radiology, Public Health, Nursing and Medicine, IDIS-CIMUS, University of Santiago de Compostela, 15706 Santiago de Compostela, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2852-7851","authenticated-orcid":false,"given":"David","family":"Araujo-Vilar","sequence":"additional","affiliation":[{"name":"UETeM-Molecular Pathology Group, Department of Psychiatry, Radiology, Public Health, Nursing and Medicine, IDIS-CIMUS, University of Santiago de Compostela, 15706 Santiago de Compostela, Spain"},{"name":"Division of Endocrinology and Nutrition, University Clinical Hospital of Santiago de Compostela, 15706 Santiago de Compostela, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1210\/jc.2016-2466","article-title":"The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline","volume":"101","author":"Brown","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2147\/DMSO.S130810","article-title":"Estimating the prevalence of generalized and partial lipodystrophy: Findings and challenges","volume":"10","author":"Chiquette","year":"2017","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"104073","DOI":"10.1016\/j.lpm.2021.104073","article-title":"Autoimmunity in lipodystrophy syndromes","volume":"50","author":"Ceccarini","year":"2021","journal-title":"Presse Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/00005792-200303000-00007","article-title":"Clinical features and metabolic derangements in acquired generalized lipodystrophy: Case reports and review of the literature","volume":"82","author":"Misra","year":"2003","journal-title":"Medicine"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s40618-018-0887-z","article-title":"Diagnosis and treatment of lipodystrophy: A step-bystep approach","volume":"42","author":"Santini","year":"2019","journal-title":"J. Endocrinol. Investig."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0140-6736(46)91599-1","article-title":"Lipodystrophy and hepatomegaly with diabetes, lipaemia, and other metabolic disturbances; a case throwing new light on the action of insulin","volume":"1","author":"Lawrence","year":"1946","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.3389\/fimmu.2018.02142","article-title":"Autoantibodies Against Perilipin 1 as a Cause of Acquired Generalized Lipodystrophy","volume":"9","author":"Corvillo","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2337\/db21-1086","article-title":"Characterization and Clinical Association of Autoantibodies Against Perilipin 1 in Patients with Acquired Generalized Lipodystrophy","volume":"72","author":"Corvillo","year":"2023","journal-title":"Diabetes"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2337\/db21-1172","article-title":"Autoantibodies to Perilipin-1 Define a Subset of Acquired Generalized Lipodystrophy","volume":"72","author":"Vazquez","year":"2023","journal-title":"Diabetes"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.2337\/dc18-2535","article-title":"Acquired Generalized Lipodystrophy: A New Cause of Anti-PD-1 Immune-Related Diabetes","volume":"42","author":"Jehl","year":"2019","journal-title":"Diabetes Care"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/bjd.18124","article-title":"Acquired generalized lipodystrophy under immune checkpoint inhibition","volume":"182","author":"Haddad","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.4158\/ACCR-2019-0234","article-title":"A case of acquired generalized lipodystrophy associated with pembrolizumab in a patient with metastatic malignant melanoma","volume":"6","author":"Bedrose","year":"2020","journal-title":"AACE. Clin. Case Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1210\/jc.2018-02221","article-title":"Acquired Lipodystrophy Associated with Nivolumab in a Patient with Advanced Renal Cell Carcinoma","volume":"104","author":"Falcao","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1056\/NEJMoa012437","article-title":"Leptin-replacement therapy for lipodystrophy","volume":"346","author":"Oral","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee (2022). 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2022. Diabetes Care, 45, S17\u2013S38.","DOI":"10.2337\/dc22-S002"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee (2022). 12. Retinopathy, Neuropathy, and Foot Care: Standards of Medical Care in Diabetes-2022. Diabetes Care, 45, S18\u2013S194.","DOI":"10.2337\/dc22-S012"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4237","DOI":"10.1210\/jc.2006-0178","article-title":"Androgen Excess Society. Positions statement: Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: An Androgen Excess Society guideline","volume":"91","author":"Azziz","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"263","DOI":"10.7326\/0003-4819-133-4-200008150-00009","article-title":"Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes","volume":"133","author":"Arioglu","year":"2000","journal-title":"Ann. Intern. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1210\/jcem.87.1.8176","article-title":"Intensive, long-term plasma exchange therapy for severe hypertriglyceridemia in acquired generalized lipoatrophy","volume":"87","author":"Bolan","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0002-9343(99)00414-3","article-title":"Lipodystrophies","volume":"108","author":"Garg","year":"2000","journal-title":"Am. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/1522-2586(200008)12:2<306::AID-JMRI13>3.0.CO;2-W","article-title":"Acquired generalized lipoatrophy (AGL): Highly selective MR lipid imaging and localized (1)H-MRS","volume":"12","author":"Brechtel","year":"2000","journal-title":"J. Magn. Reson. Imaging"},{"key":"ref_22","first-page":"978","article-title":"Successful pregnancy outcome in association with lipoatrophic diabetes mellitus","volume":"76","author":"Catalano","year":"1990","journal-title":"Obstet. Gynecol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1055\/s-0029-1211955","article-title":"Dysregulation of insulin-like growth factors in a case of generalized acquired lipoatrophic diabetes mellitus (Lawrence Syndrome) connected with autoantibodies against adipocyte membranes","volume":"106","author":"Hubler","year":"1998","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1346-8138.1992.tb03217.x","article-title":"Lipoatrophic diabetes","volume":"19","author":"Sasaki","year":"1992","journal-title":"J. Dermatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.ecl.2016.06.012","article-title":"Lipodystrophy Syndromes","volume":"45","author":"Hussain","year":"2016","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1210\/jc.2008-1703","article-title":"Complement abnormalities in acquired lipodystrophy revisited","volume":"94","author":"Savage","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"39","DOI":"10.4274\/jcrpe.v2i1.39","article-title":"Acquired generalized lipodystrophy associated with autoimmune hepatitis and low serum C4 level","volume":"2","author":"Eren","year":"2010","journal-title":"J Clin. Res. Pediatr. Endocrinol."},{"key":"ref_28","first-page":"44","article-title":"Infection as the source and driving force of autoimmune diseases","volume":"19","year":"2002","journal-title":"An. Med. Interna"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1210\/jc.2011-1159","article-title":"Clinical review#: Lipodystrophies: Genetic and acquired body fat disorders","volume":"96","author":"Garg","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/0026-0495(92)90173-8","article-title":"Generalized lipodystrophy: In vivo evidence for hypermetabolism and insulin-resistant lipid, glucose, and amino acid kinetics","volume":"41","author":"Klein","year":"1992","journal-title":"Metabolism"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.pathol.2018.11.004","article-title":"Lipodystrophies, dyslipidaemias and atherosclerotic cardiovascular disease","volume":"51","author":"Hussain","year":"2019","journal-title":"Pathology"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/23\/7344\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:31:28Z","timestamp":1760131888000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/23\/7344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,27]]},"references-count":31,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["jcm12237344"],"URL":"https:\/\/doi.org\/10.3390\/jcm12237344","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,27]]}}}